 Enveric Biosciences Inc. NASDAQ:ENVB said it has entered into a definitive agreement for an all-stock transaction to acquire MagicMed Industries Inc., a privately-held biotechnology company focused on creating a library of novel derivative psychedelic molecules such as psilocybin, N,N-dimethyltryptamine DMT and other molecular derivatives with applications across multiple indications. The company said the acquisition of MagicMed will expand and complement Enverics current pipeline of naturally occurring compounds, which is primarily focused on cannabinoids, to now include a robust portfolio of psychedelic-derived molecules. 